Mogroside V (MV) is a triterpenoid glycoside and a nonsugar sweetener. MV significantly ameliorated hepatic steatosis in high-fat diet- (HFD-) fed mice. Furthermore, the increased protein expression of PPAR-γ, SREBP-1, and FASN and mRNA expression of pparg, srebp1, scd1, and fasn in the liver in HFD-fed mice, which contribute to de novo lipogenesis, were dose-dependently reversed by MV treatment[3]. Mogroside V can effectively maintain normal oocyte morphology and early embryo development competence after prolonged culture for 24 h. Moreover, mogroside V can markedly reduce reactive oxygen species (ROS) levels, alleviate spindle formation and chromosome alignment abnormalities, improve mitochondrial contents, adenosine triphosphate (ATP) levels and the membrane potential (ΔΨm), and reduce early apoptosis in aged oocytes[4]. MV can protect oocytes from LPS-induced meiotic defects in part by reducing oxidative stress and maintaining m6A levels[5]. MV might alleviate oocyte meiotic defects and quality deterioration in BaP (benzo(a)pyrene)-exposed mice[6]. Mog (Mogroside V) might play a protective role against LPS-induced neurotoxicity by inhibiting the TLR4(toll-like receptor 4)-MyD88 (myeloid differentiation factor 88) and activation of AMPK/AKT-Nrf2 signaling pathway[7].
搜索
